Comparative Pharmacology
Head-to-head clinical analysis: DISOPHROL versus OPCON A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DISOPHROL versus OPCON A.
DISOPHROL vs OPCON-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Disophrol is a combination of dexbrompheniramine, a first-generation antihistamine that blocks H1 receptors, and pseudoephedrine, a sympathomimetic amine that stimulates alpha-adrenergic receptors causing vasoconstriction.
Synthetic vasopressin analog; stimulates V1 receptors on vascular smooth muscle causing vasoconstriction, and V2 receptors in renal collecting ducts increasing water reabsorption.
1 tablet (6 mg dexbrompheniramine maleate / 60 mg pseudoephedrine sulfate) orally every 4-6 hours; not to exceed 4 tablets in 24 hours.
0.1% ophthalmic solution: 1 drop in the affected eye(s) every 3-4 hours as needed for redness relief.
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in adults; in renal impairment, half-life may be prolonged up to 8-12 hours requiring dose adjustment.
Terminal elimination half-life is approximately 2-4 hours in healthy adults; may be prolonged in renal impairment.
Renal excretion of unchanged drug and metabolites; approximately 60-70% of a dose eliminated in urine as unchanged drug and glucuronide conjugates, with <10% in feces.
Primarily renal excretion of unchanged drug and metabolites; about 70-80% of the dose eliminated via urine within 24 hours, with 10-20% fecal elimination.
Category C
Category C
Antihistamine/Decongestant Combination
Ophthalmic Antihistamine/Decongestant Combination